| Literature DB >> 29020406 |
Thierry Le Tourneau1,2, Solena Le Scouarnec1, Caroline Cueff1,2, Daniel Bernstein3, Jan J J Aalberts4, Simon Lecointe1, Jean Mérot1, Jonathan A Bernstein5, Toon Oomen6, Christian Dina1,2, Matilde Karakachoff1,2, Hubert Desal1, Ousama Al Habash2, Francesca N Delling7, Romain Capoulade1,2,8, Albert J H Suurmeijer9, David Milan10, Russell A Norris11, Roger Markwald11, Elena Aikawa12, Susan A Slaugenhaupt13, Xavier Jeunemaitre14,15,16, Albert Hagège14,15,16, Jean-Christian Roussel1,2, Jean-Noël Trochu1,2, Robert A Levine8, Florence Kyndt1, Vincent Probst1,2, Hervé Le Marec1,2, Jean-Jacques Schott1,2.
Abstract
Aims: Filamin-A (FLNA) was identified as the first gene of non-syndromic mitral valve dystrophy (FLNA-MVD). We aimed to assess the phenotype of FLNA-MVD and its impact on prognosis. Methods and results: We investigated the disease in 246 subjects (72 mutated) from four FLNA-MVD families harbouring three different FLNA mutations. Phenotype was characterized by a comprehensive echocardiography focusing on mitral valve apparatus in comparison with control relatives. In this X-linked disease valves lesions were severe in men and moderate in women. Most men had classical features of mitral valve prolapse (MVP), but without chordal rupture. By contrast to regular MVP, mitral leaflet motion was clearly restricted in diastole and papillary muscles position was closer to mitral annulus. Valvular abnormalities were similar in the four families, in adults and young patients from early childhood suggestive of a developmental disease. In addition, mitral valve lesions worsened over time as encountered in degenerative conditions. Polyvalvular involvement was frequent in males and non-diagnostic forms frequent in females. Overall survival was moderately impaired in men (P = 0.011). Cardiac surgery rate (mainly valvular) was increased (33.3 ± 9.8 vs. 5.0 ± 4.9%, P < 0.0001; hazard ratio 10.5 [95% confidence interval: 2.9-37.9]) owing mainly to a lifetime increased risk in men (76.8 ± 14.1 vs. 9.1 ± 8.7%, P < 0.0001).Entities:
Mesh:
Substances:
Year: 2018 PMID: 29020406 PMCID: PMC5905589 DOI: 10.1093/eurheartj/ehx505
Source DB: PubMed Journal: Eur Heart J ISSN: 0195-668X Impact factor: 35.855